Clinical Trial Detail

NCT ID NCT03226249
Title PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Northwestern University
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Age Groups: adult senior

No variant requirements are available.